[HTML][HTML] Eculizumab therapy in children with severe hematopoietic stem cell transplantation–associated thrombotic microangiopathy

S Jodele, T Fukuda, A Vinks, K Mizuno… - Biology of Blood and …, 2014 - Elsevier
We recently observed that dysregulation of the complement system may be involved in the
pathogenesis of hematopoietic stem cell transplantation–associated thrombotic …

Novel detection assay by PCR–RFLP and frequency of the CYP3A5 SNPs, CYP3A5* 3 and* 6, in a Japanese population

S Fukuen, T Fukuda, H Maune, Y Ikenaga… - Pharmacogenetics …, 2002 - journals.lww.com
In this study, we established useful and reliable methods for the direct detection of the variants
of CYP3A5 gene by polymerase chain reaction (PCR) and Dde I restriction analysis. The …

Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group

…, JM DeSesso, J Fisher, T Fukuda… - Clinical …, 2015 - Wiley Online Library
The critical importance of membrane‐bound transporters in pharmacotherapy is widely
recognized, but little is known about drug transporter activity in children. In this white paper, the …

[HTML][HTML] Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell …

S Jodele, T Fukuda, K Mizuno, AA Vinks… - Biology of blood and …, 2016 - Elsevier
Thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT)
associated with terminal complement activation, as measured by elevated plasma terminal …

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in …

M Kato, T Fukuda, M Wakeno, K Fukuda… - …, 2006 - karger.com
In this study, we tested the influence of the serotonin type 2A, 3A and 3B receptor genes (HTR2A,
HTR3A, HTR3B) in addition to a polymorphism in the promoter region of the serotonin …

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder

M Kato, T Fukuda, A Serretti, M Wakeno… - Progress in Neuro …, 2008 - Elsevier
Variability in antidepressant response is due to genetic and environmental factors. Among
genetic factors, the ones controlling for availability of the drug at the target site are interesting …

[HTML][HTML] NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related …

…, S Goldman, AA Vinks, C Emoto, T Fukuda… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform
neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the …

Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease.

T Sugimura, H Kato, O Inoue, T Fukuda, N Sato… - Circulation, 1994 - Am Heart Assoc
BACKGROUND The long-term clinical issue in Kawasaki disease (KD) concerns the coronary
artery lesion. Two-dimensional echocardiography and coronary angiography are routine …

Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly

T Fukuda, A Tokunaga, R Sakamoto… - Molecular and Cellular …, 2011 - Elsevier
Histone methylation is the important transcription regulatory system that affects mammalian
development and cell differentiation. Alterations in epigenetic gene regulation are associated …

OCT1 genetic variants influence the pharmacokinetics of morphine in children

T Fukuda, V Chidambaran, T Mizuno… - …, 2013 - Future Medicine
Aim: Large interindividual variability in morphine disposition could contribute to unpredictable
variability in morphine analgesia and adverse events. Caucasian children have more …